Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

Breast Cancer Research and Treatment

Volumn 93, Issue 1, 2005, Pages 3-11

  Dybdal, Noël ^a   Leiberman, Grazyna ^a   Anderson, Steven ^b   McCune, Bryan ^b   Bajamonde, Alex ^a   Cohen, Robert L ^a   Mass, Robert D ^a   Sanders, Corsee ^a   Press, Michael F ^c  

^a GENENTECH INC   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Fluorescence in situ hybridization (FISH); HER2; Immunohistochemistry (IHC); Metastatic breast cancer (MBC); Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM METASTASIS; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS;

EID: 25144453930     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-6275-8     Document Type: Article

References (53)

1. T Akiyama C Sudo H Ogawara K Toyoshima T Yamamoto 1986 The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 1644 1646
2. L Coussens TL Yang-Feng YC Liao E Chen A Gray J McGrath PH Seeburg TA Libermann J Schlessinger U Francke 1985 Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science 230 1132 1139
3. DF Stern PA Heffernan RA Weinberg 1986 p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity Mol Cell Biol 6 1729 1740
4. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182
5. G Pauletti S Dandekar H Rong 1998 A large-scale FISH study of HER-2/neu gene amplification in breast cancer. Proc Am Assoc Cancer Res 39 345 (Abstract 2352)
6. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712
7. OP Kallioniemi A Kallioniemi W Kurisu A Thor LC Chen HS Smith FM Waldman D Pinkel JW Gray 1992 ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization Proc Natl Acad Sci USA 89 5321 5325
8. BA Gusterson RD Gelber A Goldhirsch KN Price J Save-Soderborgh R Anbazhagan J Styles CM Rudenstam R Golouh R Reed 1992 Prognostic importance of c-erbB-2 expression in breast cancer.International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 1049 1056
9. IL Andrulis SB Bull ME Blackstein D Sutherland C Mak S Sidlofsky KP Pritzker RW Hartwick W Hanna L Lickley R Wilkinson A Qizilbash U Ambus M Lipa H Weizel A Katz M Baida S Mariz G Stoik P Dacamara D Strongitharm W Geddie D McCready 1998 neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer.Toronto Breast Cancer Study Group J Clin Oncol 16 1340 1349
10. MF Press MC Pike VR Chazin G Hung JA Udove M Markowicz J Danyluk W Godolphin M Sliwkowski R Akita 1993 Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease Cancer Res 53 4960 4970
11. MF Press L Bernstein PA Thomas LF Meisner JY Zhou Y Ma G Hung RA Robinson C Harris A El-Naggar DJ Slamon RN Phillips JS Ross SR Wolman KJ Flom 1997 HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 2894 2904
12. VR Chazin M Kaleko AD Miller DJ Slamon 1992 Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor Oncogene 7 1859 1866
13. P Carter L Presta CM Gorman JB Ridgway D Henner WL Wong AM Rowland C Kotts ME Carver HM Shepard 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285 4289
14. MA Cobleigh CL Vogel D Tripathy NJ Robert S Scholl L Fehrenbacher JM Wolter V Paton S Shak G Lieberman DJ Slamon 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648
15. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
16. CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart M Press 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726
17. G Pauletti W Godolphin MF Press DJ Slamon 1996 Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization Oncogene 13 63 72
18. G Pauletti S Dandekar H Rong L Ramos H Peng R Seshadri DJ Slamon 2000 Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry J Clin Oncol 18 3651 3664
19. MF Press G Hung W Godolphin DJ Slamon 1994 Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression Cancer Res 54 2771 2777
20. RR Tubbs JD Pettay PC Roche MH Stoler RB Jenkins TM Grogan 2001 Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message J Clin Oncol 19 2714 2721
21. A Lebeau D Deimling C Kaltz A Sendelhofert A Iff B Luthardt M Untch U Lohrs 2001 Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization J Clin Oncol 19 354 363
22. RE Jimenez T Wallis P Tabasczka DW Visscher 2000 Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization Mod Pathol 13 37 45
23. JM Bartlett JJ Going EA Mallon AD Watters JR Reeves P Stanton J Richmond B Donald R Ferrier TG Cooke 2001 Evaluating HER2 amplification and overexpression in breast cancer J Pathol 195 422 428
24. NM Diaz 2001 Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy Cancer Control 8 415 418
25. TW Jacobs AM Gown H Yaziji MJ Barnes SJ Schnitt 1999 Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer J Clin Oncol 17 1974 1982
26. S Kakar N Puangsuvan JM Stevens R Serenas G Mangan S Sahai ML Mihalov 2000 HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival Mol Diagn 5 199 207
27. RL Ridolfi MR Jamehdor JM Arber 2000 HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach Mod Pathol 13 866 873
28. EA Perez PC Roche RB Jenkins CA Reynolds KC Halling JN Ingle LE Wold 2002 HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization Mayo Clin Proc 77 148 154
29. TA Thomson MM Hayes JJ Spinelli E Hilland C Sawrenko D Phillips B Dupuis RL Parker 2001 HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization Mod Pathol 14 1079 1086
30. MP Hoang AA Sahin NG Ordonez N Sneige 2000 HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma Am J Clin Pathol 113 852 859
31. AD Seidman MN Fornier FJ Esteva L Tan S Kaptain A Bach KS Panageas C Arroyo V Valero V Currie T Gilewski M Theodoulou ME Moynahan M Moasser N Sklarin M Dickler G D'Andrea M Cristofanilli E Rivera GN Hortobagyi L Norton CA Hudis 2001 Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J Clin Oncol 19 2587 2595
32. DL Persons KA Borelli PH Hsu 1997 Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization Mod Pathol 10 720 727
33. H Tsuda F Akiyama H Terasaki T Hasegawa M Kurosumi M Shimadzu S Yamamori G Sakamoto 2001 Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 92 2965 2974
34. P Birner G Oberhuber J Stani C Reithofer H Samonigg H Hausmaninger E Kubista W Kwasny D Kandioler-Eckersberger M Gnant R Jakesz 2001 Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer Clin Cancer Res 7 1669 1675
35. MF Press DJ Slamon KJ Flom J Park JY Zhou L Bernstein 2002 Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol 20 3095 3105
36. S Paik J Bryant E Tan-Chiu E Romond W Hiller K Park A Brown G Yothers S Anderson R Smith DL Wickerham N Wolmark 2002 Real-world performance of HER2 testing. National Surgical Adjuvant Breast and Bowel Project experience J Natl Cancer Inst 94 852 854
37. J Fleiss 1981 Statistical Methods of Rates and Proportions 2 John Wiley & Sons, Inc New York 217
38. Mass RD, Press MF, Anderson S: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer, 2005 (in press).
39. JS Ross JA Fletcher 1998 The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy Stem Cells 16 413 428
40. H Battifora M Kopinski 1986 The influence of protease digestion and duration of fixation on the immunostaining of keratins A comparison of formalin and ethanol fixation. J Histochem Cytochem 34 1095 1100
41. F Penault-Llorca J Adelaide G Houvenaeghel J Hassoun D Birnbaum J Jacquemier 1994 Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation J Pathol 173 65 75
42. TW Jacobs AM Gown H Yaziji MJ Barnes SJ Schnitt 1999 Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system J Clin Oncol 17 1983 1987
43. Owens MA Horten BC Da Silva MM 2004 HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues Clin Breast Cancer 5 63 69
44. Press MF SG, Bernstein L, Mirlacher M, Villalobos I, Zhou J, Riva A, Nabholtz JM, Slamon DJ: Diagnostic evaluation of HER-2/neu as a molecular therapeutic target: local testing versus centralized FISH testing. Lab Invest 83: 43a, 2003
45. GA Niehans TP Singleton D Dykoski DT Kiang 1993 Stability of HER-2/neu expression over time and at multiple metastatic sites J Natl Cancer Inst 85 1230 1235
46. A Vincent-Salomon M Jouve P Genin P Freneaux B Sigal-Zafrani M Caly P Beuzeboc P Pouillart X Sastre-Garau 2002 HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process Cancer 94 2169 2173
47. R Simon A Nocito T Hubscher C Bucher J Torhorst P Schraml L Bubendorf MM Mihatsch H Moch K Wilber A Schotzau J Kononen G Sauter 2001 Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 93 1141 1146
48. S Masood MM Bui 2000 Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study Ann Clin Lab Sci 30 259 265
49. S Paik E Tan-Chiu J Bryant E Romond A Brown J Mull W Hiller M Finnigan N Wolmark 2002 Successful quality assurance program for HER2 testing in the NSABP trial for Herceptin Breast Cancer Res Treat 76 S31
50. J Bartlett E Mallon T Cooke 2003 The clinical evaluation of HER-2 status: which test to use J Pathol 199 411 417
51. CAP 2002 Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing Arch Pathology Lab Med 126 803 808
52. PJ vDP van Diest SC Henzen-Logmans E Berns ME van der Burg J Green I Vergote 1997 A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group J Clin Pathol 50 801 804
53. JJ Going L Mallon JR Reeves AD Watters J Richmond B Donald R Ferrier T Cooke J Bartlett 2000 Inter-observer agreement in assessing C-ERBB-2 status in breast cancer: immunhistochemistry and FISH. J Pathol 190 (Suppl) 19A